These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 34503164)

  • 41. The Role of MicroRNAs in Diagnosis, Prognosis, Metastasis and Resistant Cases in Breast Cancer.
    Teoh SL; Das S
    Curr Pharm Des; 2017; 23(12):1845-1859. PubMed ID: 28231756
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MicroRNA profiling reveals dysregulated microRNAs and their target gene regulatory networks in cemento-ossifying fibroma.
    Pereira TDSF; Brito JAR; Guimarães ALS; Gomes CC; de Lacerda JCT; de Castro WH; Coimbra RS; Diniz MG; Gomez RS
    J Oral Pathol Med; 2018 Jan; 47(1):78-85. PubMed ID: 29032608
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A panel of serum exosomal microRNAs as predictive markers for chemoresistance in advanced colorectal cancer.
    Jin G; Liu Y; Zhang J; Bian Z; Yao S; Fei B; Zhou L; Yin Y; Huang Z
    Cancer Chemother Pharmacol; 2019 Aug; 84(2):315-325. PubMed ID: 31089750
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reconstruction of temporal activity of microRNAs from gene expression data in breast cancer cell line.
    Jayavelu ND; Bar N
    BMC Genomics; 2015 Dec; 16():1077. PubMed ID: 26763900
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oncogenic miRNAs and target therapies in colorectal cancer.
    Saberinia A; Alinezhad A; Jafari F; Soltany S; Akhavan Sigari R
    Clin Chim Acta; 2020 Sep; 508():77-91. PubMed ID: 32407782
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of microRNAs in skeletal muscle associated with lung cancer cachexia.
    van de Worp WRPH; Schols AMWJ; Dingemans AC; Op den Kamp CMH; Degens JHRJ; Kelders MCJM; Coort S; Woodruff HC; Kratassiouk G; Harel-Bellan A; Theys J; van Helvoort A; Langen RCJ
    J Cachexia Sarcopenia Muscle; 2020 Apr; 11(2):452-463. PubMed ID: 31828982
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types.
    Hummel R; Hussey DJ; Haier J
    Eur J Cancer; 2010 Jan; 46(2):298-311. PubMed ID: 19948396
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of miRNA-210, miRNA-21 and miRNA-126 as diagnostic biomarkers in colorectal carcinoma: impact of HIF-1α-VEGF signaling pathway.
    Sabry D; El-Deek SEM; Maher M; El-Baz MAH; El-Bader HM; Amer E; Hassan EA; Fathy W; El-Deek HEM
    Mol Cell Biochem; 2019 Apr; 454(1-2):177-189. PubMed ID: 30357530
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Site-specific associations between miRNA expression and survival in colorectal cancer cases.
    Slattery ML; Herrick JS; Pellatt DF; Mullany LE; Stevens JR; Wolff E; Hoffman MD; Wolff RK; Samowitz W
    Oncotarget; 2016 Sep; 7(37):60193-60205. PubMed ID: 27517623
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Data Mining the Prognostic Biomarkers: miRNAs Targeting the Chemotherapeutic Agent 5-Fluorouracil in Colon Cancer.
    Wu XX; Huang XL; Lin XR; Li YL; Chen YH; Huang ZM
    Clin Lab; 2020 Mar; 66(3):. PubMed ID: 32162886
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance.
    Yang L; Li N; Wang H; Jia X; Wang X; Luo J
    Oncol Rep; 2012 Aug; 28(2):592-600. PubMed ID: 22614869
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principle.
    Ahmed FE; Ahmed NC; Vos PW; Bonnerup C; Atkins JN; Casey M; Nuovo GJ; Naziri W; Wiley JE; Mota H; Allison RR
    Cancer Genomics Proteomics; 2013; 10(3):93-113. PubMed ID: 23741026
    [TBL] [Abstract][Full Text] [Related]  

  • 53. miR-221 Targets QKI to Enhance the Tumorigenic Capacity of Human Colorectal Cancer Stem Cells.
    Mukohyama J; Isobe T; Hu Q; Hayashi T; Watanabe T; Maeda M; Yanagi H; Qian X; Yamashita K; Minami H; Mimori K; Sahoo D; Kakeji Y; Suzuki A; Dalerba P; Shimono Y
    Cancer Res; 2019 Oct; 79(20):5151-5158. PubMed ID: 31416845
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Pathway Analysis of Micrornas Regulated Drug-Resistant Responses in HeLa Cells.
    Yang Y; Dai C; Cai Z; Hou A; Cheng D; Wu G; Li J; Cui J; Xu D
    IEEE Trans Nanobioscience; 2016 Mar; 15(2):113-8. PubMed ID: 27019498
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interactive functions of microRNAs in the miR-23a-27a-24-2 cluster and the potential for targeted therapy in cancer.
    Cui M; Yao X; Lin Y; Zhang D; Cui R; Zhang X
    J Cell Physiol; 2020 Jan; 235(1):6-16. PubMed ID: 31192453
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A systems biology approach to identify microRNAs contributing to cisplatin resistance in human ovarian cancer cells.
    Liu W; Wang S; Zhou S; Yang F; Jiang W; Zhang Q; Wang L
    Mol Biosyst; 2017 Oct; 13(11):2268-2276. PubMed ID: 28861582
    [TBL] [Abstract][Full Text] [Related]  

  • 57. miR-92 is a key oncogenic component of the miR-17-92 cluster in colon cancer.
    Tsuchida A; Ohno S; Wu W; Borjigin N; Fujita K; Aoki T; Ueda S; Takanashi M; Kuroda M
    Cancer Sci; 2011 Dec; 102(12):2264-71. PubMed ID: 21883694
    [TBL] [Abstract][Full Text] [Related]  

  • 58. miR-150, p53 protein and relevant miRNAs consist of a regulatory network in NSCLC tumorigenesis.
    Wang DT; Ma ZL; Li YL; Wang YQ; Zhao BT; Wei JL; Qi X; Zhao XT; Jin YX
    Oncol Rep; 2013 Jul; 30(1):492-8. PubMed ID: 23670238
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Integrated analysis of the differential cellular and EBV miRNA expression profiles in microdissected nasopharyngeal carcinoma and non-cancerous nasopharyngeal tissues.
    Wan XX; Yi H; Qu JQ; He QY; Xiao ZQ
    Oncol Rep; 2015 Nov; 34(5):2585-601. PubMed ID: 26330189
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment.
    Ragusa M; Majorana A; Statello L; Maugeri M; Salito L; Barbagallo D; Guglielmino MR; Duro LR; Angelica R; Caltabiano R; Biondi A; Di Vita M; Privitera G; Scalia M; Cappellani A; Vasquez E; Lanzafame S; Basile F; Di Pietro C; Purrello M
    Mol Cancer Ther; 2010 Dec; 9(12):3396-409. PubMed ID: 20881268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.